ARCHIVES

Health Reform Plans Offer Difficult Choices For Patients, Researchers, Practitioners

This article is from The Cancer Letter archive.

Vol. 20 No. 08 | February 25, 1994

Download PDF Visit The Full Archive

Related Articles

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

Study Recommends Longer Courses Of Chemotherapy For Bone Marrow Cancer

March 31, 2006

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002

Imaging Technique Identifies Consequences Of Mutation

February 24, 2012

IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer

October 28, 2011

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

October 29, 2010